Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients.

Trial Profile

Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 30 May 2014

At a glance

  • Drugs Fluorouracil (Primary) ; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCORD11
  • Most Recent Events

    • 30 May 2014 Biomarker analysis (CA19-9 response) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2013 According to a Yakult Honsha media release, the company has submitted supplemental new drug applications relating to an additional indication for pancreatic cancer, with respect to its products, Campto (40mg and 100mg), Elplat (50mg, 100mg and 200mg), and Levofolinate [Yakult] (25mg and 100mg), to the Japanese Ministry of Health, Labor and Welfare (MHLW).
    • 12 May 2011 Results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top